Candel Therapeutics (CADL) has issued an update.
Candel Therapeutics, Inc. is set to unveil a pioneering immunotherapy candidate at the American Association for Cancer Research Annual Meeting on April 9, 2024. This second candidate, emerging from their enLIGHTENTM Discovery Platform, is designed to induce tertiary lymphoid structures and enhance anti-tumor immunity in solid tumors. Utilizing advanced analytics and in silico predictions, the therapy has shown promising results in mouse models, both alone and when combined with existing anti-PD-1 antibody treatments.
For detailed information about CADL stock, go to TipRanks’ Stock Analysis page.
